What is the initial management of acute pulmonary embolism?

Initial Treatment for Acute Pulmonary Embolism

Initiate anticoagulation immediately upon suspicion of acute PE, even before diagnostic confirmation is complete, unless the patient has active bleeding or absolute contraindications to anticoagulation. 1

Immediate Anticoagulation Strategy

For Hemodynamically Stable Patients (Intermediate- or Low-Risk PE)

Start with parenteral anticoagulation or a direct oral anticoagulant (NOAC) as first-line therapy:

• Preferred approach: Low molecular weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH) for most patients 1
• Weight-adjusted LMWH dosing is superior to standard UFH in stable patients 1
• Direct oral anticoagulants (NOACs) - apixaban, rivaroxaban, edoxaban, or dabigatran - are recommended over vitamin K antagonists (VKA) when oral anticoagulation is initiated 1
• If using a VKA, overlap with parenteral anticoagulation until INR reaches 2.0-3.0 (target 2.5) 1

NOAC contraindications include: severe renal impairment, pregnancy, lactation, and antiphospholipid antibody syndrome 1

For Hemodynamically Unstable Patients (High-Risk PE)

Unfractionated heparin with weight-adjusted bolus injection is the anticoagulant of choice:

• Initial bolus: 80 IU/kg IV 1
• Maintenance infusion: 18 IU/kg/hour 1
• Target APTT: 1.5-2.5 times control (45-75 seconds) 1
• Monitor APTT: 4-6 hours after initial bolus, 6-10 hours after dose changes, then daily once therapeutic 1

Reperfusion Therapy for High-Risk PE

Systemic thrombolytic therapy is the recommended first-line reperfusion treatment for high-risk PE (patients with hemodynamic instability/shock). 1

Thrombolytic Regimens

Stop heparin before initiating thrombolysis: 1

• rtPA: 100 mg IV over 2 hours 1
• Streptokinase: 250,000 units IV over 20 minutes, then 100,000 units/hour for 24 hours (plus hydrocortisone to prevent circulatory instability) 1
• Urokinase: 4,400 IU/kg IV over 10 minutes, then 4,400 IU/kg/hour for 12 hours 1

Alternative Reperfusion Options

When thrombolysis is contraindicated or has failed:

• Surgical pulmonary embolectomy is recommended 1
• Percutaneous catheter-directed treatment should be considered 1
• ECMO may be considered in combination with surgical embolectomy or catheter-directed treatment for patients with refractory circulatory collapse or cardiac arrest 1

Hemodynamic Support

For patients with high-risk PE and shock:

• Norepinephrine and/or dobutamine should be considered for hemodynamic support 1

Risk Stratification Drives Treatment Intensity

The British Thoracic Society guidelines emphasize assessing clinical probability before treatment, looking for: 1

• High-risk patterns: sudden collapse with elevated JVP, faintness/hypotension
• Pulmonary hemorrhage syndrome: pleuritic pain and/or hemoptysis
• Isolated dyspnea: breathlessness without cough, sputum, or chest pain
• Major risk factors: recent immobilization/surgery, lower limb trauma/surgery, clinical DVT, previous DVT/PE, pregnancy/postpartum, major medical illness 1

Critical Pitfalls to Avoid

PE is easily missed in: 1

• Severe cardiorespiratory disease
• Elderly patients
• Patients with isolated dyspnea as the only symptom

Most patients with PE are breathless and/or tachypneic (respiratory rate >20/min) 1

Do not delay anticoagulation while awaiting diagnostic confirmation - the risk-benefit strongly favors immediate treatment in suspected PE 1

Rescue thrombolytic therapy is recommended for patients who deteriorate hemodynamically despite anticoagulation 1

Routine primary systemic thrombolysis is NOT recommended for intermediate- or low-risk PE 1